Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 10;10(24):5777.
doi: 10.3390/jcm10245777.

Comparison of Conservative Treatment of Cervical Intraepithelial Lesions with Imiquimod with Standard Excisional Technique Using LLETZ: A Randomized Controlled Trial

Andrej Cokan  1 , Maja Pakiž  1 , Tamara Serdinšek  2 , Andraž Dovnik  1 , Tatjana Kodrič  1 , Alenka Repše Fokter  3   4 , Rajko Kavalar  5 , Igor But  2
Affiliations

Comparison of Conservative Treatment of Cervical Intraepithelial Lesions with Imiquimod with Standard Excisional Technique Using LLETZ: A Randomized Controlled Trial

Andrej Cokan et al. J Clin Med. .

Abstract

(1) Background: There are limited data on the success of conservative treatment of high-grade cervical squamous intraepithelial lesions (HSIL) with imiquimod directly compared to standard of treatment with LLETZ. (2) Methods: Patients aged 18-40 with histological HSIL (with high-grade cervical intraepithelial neoplasia, CIN2p16+ and CIN3), were randomly assigned to treatment with imiquimod or LLETZ. The primary outcome was defined as the absence of HSIL after either treatment modality. The secondary outcomes were the occurrence of side effects. (3) Results: 52 patients were allocated in each group and were similar regarding baseline characteristics. In the imiquimod group, 82.7% of patients completed treatment, which was successful in 51.9%. All patients in the LLETZ group completed treatment, which was successful in 92.3% (p < 0.001). In the subgroup of CIN2p16+ patients, treatment with imiquimod was not inferior to LLETZ (73.9% vs. 84.2%, p = 0.477). During and after treatment, no cases of progression to cancer were observed. Side effects and severe side effects (local and systemic) were more prevalent in the imiquimod than in the LLETZ group (88.5% vs. 44.2% (p-value < 0.001) and 51.9% vs. 13.5% (p-value < 0.001), respectively). (4) Conclusion: Generally, in patients with HSIL, LLETZ remains the gold standard of treatment. However, in a subgroup analysis of patients with CIN2p16+, the success rate was comparable between the two treatment modalities. Due to the prevalence of side effects, the treatment compliance with imiquimod use may, however, present a clinically important issue.

Keywords: LLETZ; imiquimod; randomized controlled trial; squamous intraepithelial lesion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study.
See this image and copyright information in PMC

References

    1. Peirson L., Fitzpatrick-Lewis D., Ciliska D., Warren R. Screening for cervical cancer: A systematic review and meta-analysis. Syst. Rev. 2013;2:35. doi: 10.1186/2046-4053-2-35. - DOI - PMC - PubMed
    1. Vaccarella S., Franceschi S., Engholm G., Lönnberg S., Khan S., Bray F. 50 years of screening in the Nordic countries: Quantifying the effects on cervical cancer incidence. Br. J. Cancer. 2014;111:965–969. doi: 10.1038/bjc.2014.362. - DOI - PMC - PubMed
    1. Uršič Vrščaj M. Smernice za Celostno Obravnavo Žensk s Predrakavimi Spremembami Materničnega Vratu. 2011. [(accessed on 28 November 2021)]. Available online: https://zora.onko-i.si/fileadmin/user_upload/dokumenti/strokovna_priporo....
    1. Zadnik V., Zakelj M.P., Lokar K., Jarm K., Ivanus U., Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol. Oncol. 2017;51:47–55. doi: 10.1515/raon-2017-0008. - DOI - PMC - PubMed
    1. Žakelj M.P., Zadnik V., Pogačnik A., Vrščaj M.U. Presejanje za raka materničnega vratu v Sloveniji in državni program ZORA. Radiol. Oncol. 2006;40:S143–S148.

LinkOut - more resources